Do you want to read an article? Please log in or register.
CROWN: ctDNA analyses identify potential predictors of early progression with first-line lorlatinib in patients with ALK-positive NSCLC
Lung, Respiratory and Thoracic Cancer
ESMO 2026
Related content
Lung, Respiratory and Thoracic Cancer
Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer: 7-year update from the phase 3 CROWN study
Ann Oncol
Shaw AT, Solomon BJ, Felip E, Bauer TM, Liu G, Goto Y, Wu YL, Soo RA, Mazieres J, Kim DW, Wang IM, Paolini J, Polli A, Rifi N, Toffalorio F, Mok TSK
doi: 10.1016/j.annonc.2026.05.692
CHICAGO 2026
Lung, Respiratory and Thoracic Cancer
CROWN: Persistent 7-year PFS benefits with lorlatinib versus crizotinib in advanced ALK-positive NSCLC
RECOMMENDED
Head and Neck Cancer
Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Liu G, Abrahami D, Ramachandran P, Messina R, Rifi N, Yang H, Chai X, Li B, Ramaswamy K, Iyengar P, Pennell NA, Shaw AT
doi: 10.1016/j.lungcan.2025.108858
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Adv Ther
Girard N, Macouillard P, Byng D, Meng J, Coerts F, Hunter S, Struebing A, Xiong Y, Park S, Haq MI, Tymejczyk O, Chouaid C, Audigier-Valette C, Debieuvre D, Quantin X, Bosquet L, Pérol M
doi: 10.1007/s12325-025-03465-4
Lung, Respiratory and Thoracic Cancer
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC
Lung Cancer
Paz-Ares L, Veillon R, Majem M, Zhou C, Tang KJ, Kim SW, Richardson G, Girard N, Sanborn RE, Mansfield AS, Park K, Schuchard J, Diels J, Sermon J, Bhattacharya A, Lorenzini P, Wortman-Vayn H, Knoblauch RE, Agrawal T, Baig M, Ono A, Sabari JK
doi: 10.1016/j.lungcan.2025.108788
Breast Cancer
Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease
Ann Oncol
Curigliano G, Hu X, Dent R, Yonemori K, Barrios CH, Pierga JY, Puglisi F, Ferrero JM, Jung KH, Bagegni NA, Collignon J, Gil-Gil M, Wu X, Andrzejuk-Ćwik A, Schwaederle M, Anand S, Bardia A
doi: 10.1016/j.annonc.2026.02.015
SABCS 2025
Breast Cancer
PALLAS: Predictors of early palbociclib discontinuation in patients with early breast cancer
WCLC 2026
Lung, Respiratory and Thoracic Cancer
Actionable Genomic Alterations in NSCLC: What is Changing in Testing and Treatment?
Lung, Respiratory and Thoracic Cancer
Comparative effectiveness of first-line targeted therapies in ALK-positive non-small cell lung cancer: real-world evidence of tyrosine kinase inhibitors
Lung Cancer
Mudumba R, Liu X, Jin S, Davis IJ, Baid D, Romley JA, Nieva JJ
doi: 10.1016/j.lungcan.2026.109451